ERBB2 and neoplasm: Canonical cancer stem cell (CSC) phenotypes—CD44hi/CD24locells and ALDHhi—have been documented to sustain tumour growth and resistance to conventional anticancer therapies (for example, anti-Her2 and chemotherapy/radiation therapy) in several tumour models1, 2, 3.